Compare, Analyse AJANTA PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   ACTAVIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
ACTAVIS
Dec-18
AJANTA PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,42214,315-   
Low Rs8989,603-   
Sales per share (Unadj.) Rs233.53,511.5-  
Earnings per share (Unadj.) Rs44.0-1,131.1-  
Cash flow per share (Unadj.) Rs52.2370.0-  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.114,483.3-  
Shares outstanding (eoy) m88.02332.60-   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.03.4 145.8%   
Avg P/E ratio x26.4-10.6 -249.5%  
P/CF ratio (eoy) x22.232.3 68.8%  
Price / Book Value ratio x4.50.8 550.6%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,0813,977,519 2.6%   
No. of employees `0006.816.9 40.2%   
Total wages/salary Rs m4,3070-   
Avg. sales/employee Rs Th3,022.669,107.8 4.4%   
Avg. wages/employee Rs Th633.40-   
Avg. net profit/employee Rs Th569.1-22,259.7 -2.6%   
INCOME DATA
Net Sales Rs m20,5541,167,922 1.8%  
Other income Rs m21122,335 0.9%   
Total revenues Rs m20,7651,190,257 1.7%   
Gross profit Rs m5,66430,606 18.5%  
Depreciation Rs m721499,261 0.1%   
Interest Rs m1267,396 0.0%   
Profit before tax Rs m5,143-513,717 -1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0131,019 0.0%   
Tax Rs m1,273-6,510 -19.6%   
Profit after tax Rs m3,870-376,188 -1.0%  
Gross profit margin %27.62.6 1,051.6%  
Effective tax rate %24.81.3 1,953.3%   
Net profit margin %18.8-32.2 -58.5%  
BALANCE SHEET DATA
Current assets Rs m11,812479,021 2.5%   
Current liabilities Rs m3,776423,757 0.9%   
Net working cap to sales %39.14.7 826.3%  
Current ratio x3.11.1 276.7%  
Inventory Days Days7720 395.1%  
Debtors Days Days8266 123.1%  
Net fixed assets Rs m14,398132,202 10.9%   
Share capital Rs m1750-   
"Free" reserves Rs m22,2770-   
Net worth Rs m22,4524,817,134 0.5%   
Long term debt Rs m71,696,287 0.0%   
Total assets Rs m26,9627,530,276 0.4%  
Interest coverage x444.3-6.6 -6,709.6%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.80.2 491.5%   
Return on assets %14.4-4.1 -351.1%  
Return on equity %17.2-7.8 -220.7%  
Return on capital %23.0-4.8 -474.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m8,5800-   
CASH FLOW
From Operations Rs m3,748417,255 0.9%  
From Investments Rs m-2,228229,227 -1.0%  
From Financial Activity Rs m-1,475-716,134 0.2%  
Net Cashflow Rs m45-69,304 -0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.98 Rs / USD

Compare AJANTA PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: SUN PHARMA  NOVARTIS  IPCA LABS  STRIDES PHARMA SCIENCE  VENUS REMEDIES  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views On News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living (Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Access Now: Eight Steps to Your Eight Figure Fortune
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

AJANTA PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AJANTA PHARMA

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

FEATURED VIDEOS

Nifty is Weak but Smallcaps Can Outperform

Gold 65,000 and Silver 84,000 in 2022

How Long Before a Big Stock Market Crash

I Believe the Investment of the Year Will Be...

More Featured Videos

MARKET STATS